Efficacy and safety of the dipeptidyl peptidase-4 inhibitor sitagliptin added to ongoing pioglitazone therapy in patients with type 2 diabetes: a 24-week, multicenter, randomized, double-blind, placebo-controlled, parallel-group study. (Q51483804)
Jump to navigation
Jump to search
scientific article published in October 2006
| Language | Label | Description | Also known as |
|---|---|---|---|
| English | Efficacy and safety of the dipeptidyl peptidase-4 inhibitor sitagliptin added to ongoing pioglitazone therapy in patients with type 2 diabetes: a 24-week, multicenter, randomized, double-blind, placebo-controlled, parallel-group study. |
scientific article published in October 2006 |
Statements
1 reference
Efficacy and safety of the dipeptidyl peptidase-4 inhibitor sitagliptin added to ongoing pioglitazone therapy in patients with type 2 diabetes: a 24-week, multicenter, randomized, double-blind, placebo-controlled, parallel-group study. (English)
1 reference
Julio Rosenstock
1 reference
Ronald Brazg
1 reference
Paula J Andryuk
1 reference
Kaifeng Lu
1 reference
Peter Stein
1 reference
Sitagliptin Study 019 Group
1 reference
1 October 2006
1 reference
28
1 reference
1556-1568
1 reference
10
1 reference
Identifiers
1 reference